

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-5 (Cancelled)

6. **(Previously presented)** A method for augmenting an immune response in a patient having a cancerous or neoplastic disease, comprising the steps of administering flt3-ligand to the patient in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient.

7. **(Withdrawn)** A method according to claim 6, further comprising the step of administering one or more of the molecules selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, and fusions of GM-CSF and IL-3.

8-19 (Cancelled)

20. **(Previously presented)** A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient in an amount sufficient to enhance the patient's immune response to such disease and administering a tumor antigen to the patient.

21. (Cancelled)

22. **(Previously presented)** The method of claim 6, wherein the flt3-ligand is human flt3-ligand.

23. **(Previously presented)** The method of claim 22, wherein the flt3-ligand is soluble human flt3-ligand.

24. **(Previously presented)** The method of claim 23, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

25. **(Currently amended)** The method of claim 24, wherein the soluble human flt3-ligand has an amino acid sequence that is encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to, and is at least 90%~~80%~~ identical to, a nucleic acid that encodes an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

26. **(Previously presented)** The method of claim 24, wherein the soluble human flt3-ligand comprises an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

27. **(Previously presented)** The method of claim 6, wherein the flt3-ligand has the amino acid sequence of residues 28-163 of SEQ ID NO:2.

28. **(Previously presented)** The method of claim 26, wherein the soluble human flt3-ligand has the amino acid sequence of residues 28-160 of SEQ ID NO:1.

29. **(Previously presented)** The method of claim 6, wherein the flt3-ligand has the amino acid sequence of residues 28-188 of SEQ ID NO:2.

30. **(Previously presented)** The method of claim 26, wherein the soluble human flt3-ligand has the amino acid sequence of residues 28-182 of SEQ ID NO:1.

31. **(Previously presented)** The method of claim 20, wherein the flt3-ligand is human flt3-ligand.

32. **(Previously presented)** The method of claim 31, wherein the flt3-ligand is soluble human flt3-ligand.

33. **(Previously presented)** The method of claim 32, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

34. **(Currently amended)** The method of claim 33, wherein the soluble human flt3-ligand has an amino acid sequence that is encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to, and is at least ~~90%~~80% identical to, a nucleic acid that encodes an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

35. **(Previously presented)** The method of claim 33, wherein the soluble human flt3-ligand comprises an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

36. **(Previously presented)** The method of claim 20, wherein the flt3-ligand has the amino acid sequence of residues 28-163 of SEQ ID NO:2.
37. **(Previously presented)** The method of claim 35, wherein the soluble human flt3-ligand has the amino acid sequence of residues 28-160 of SEQ ID NO:1.
38. **(Previously presented)** The method of claim 20, wherein the flt3-ligand has the amino acid sequence of residues 28-188 of SEQ ID NO:2.
39. **(Previously presented)** The method of claim 35, wherein the soluble human flt3-ligand has the amino acid sequence of residues 28-182 of SEQ ID NO:1.
40. **(Previously presented)** The method of claim 6 wherein the cancerous disease is a tumor.
41. **(Previously presented)** The method of claim 20 wherein the cancerous disease is a tumor.
42. **(Previously presented)** The method of claim 40 wherein the tumor is a fibrosarcoma.
43. **(Previously presented)** The method of claim 41 wherein the tumor is a fibrosarcoma.
44. **(Previously presented)** The method of claim 6, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.
45. **(Previously presented)** The method of claim 6, wherein the tumor antigen is in the form of an isolated tumor antigen.
46. **(Previously presented)** The method of claim 6, wherein the antigen is administered prior to administering flt3-ligand.
47. **(Previously presented)** The method of claim 6, wherein the antigen is administered concurrently with flt3-ligand.
48. **(Previously presented)** The method of claim 6, wherein the antigen is administered after administering flt3-ligand.
49. **(Previously presented)** The method of claim 20, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.

50. **(Previously presented)** The method of claim 20, wherein the tumor antigen is in the form of an isolated tumor antigen.

51. **(Previously presented)** The method of claim 20, wherein the tumor antigen is administered prior to administering flt3-ligand.

52. **(Previously presented)** The method of claim 20, wherein the tumor antigen is administered concurrently with administering flt3-ligand .

53. **(Previously presented)** The method of claim 20, wherein the tumor antigen is administered after administering flt3-ligand .

54. **(Withdrawn)** A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient, isolating dendritic cells from the patient, exposing the dendritic cells to a tumor antigen, and administering the dendritic cells to the patient.

55. **(Withdrawn)** The method of claim 54, wherein the tumor antigen is in the form of a tumor cell bearing said antigen.

56. **(Withdrawn)** The method of claim 54, wherein the tumor antigen is in the form of an isolated tumor antigen.